![]() |
市场调查报告书
商品编码
1347346
鼻喷雾剂市场 - 按类型(类固醇、抗组胺药、减充血剂、盐水)、按应用(鼻窦炎、过敏性鼻炎、鼻息肉)、按患者(成人、儿童)、按分销渠道(医院、零售、在线)- 2023 年全球预测到2032年Nasal Spray Market - By Type (Steroid, Antihistamine, Decongestant, Saline), By Application (Sinusitis, Allergic Rhinitis, Nasal Polyps), By Patient (Adult, Pediatric), By Distribution Channel (Hospital, Retail, Online)- Global Forecast 2023 to 2032 |
由于过敏性鼻炎和鼻窦炎的患病率不断增加,预计鼻喷雾剂市场在 2023 年至 2032 年的预测时间内将出现强劲增长。
随着环境污染物的增加和生活方式的改变,越来越多的人受到这些呼吸道疾病的困扰,从而增加了对鼻喷雾剂的需求。根据世界过敏组织的数据,全世界有超过 4 亿人患有过敏性鼻炎,并且经常被误诊和治疗不足。在美国,它影响着 10-30% 的成年人口和高达 40% 的儿童,使其成为第六大流行慢性病。鼻喷雾剂可立即缓解鼻塞和相关症状,为患者提供方便的解决方案。
此外,製药公司正在积极开发创新配方,以满足这种不断增长的需求,进一步推动市场增长。举个例子,2023年5月,Bausch Health Companies Inc.宣布推出RYALTRIS(R),这是一种经加拿大卫生部授权的新型处方疗法,用于对儿童、青少年中度、轻度至重度季节性过敏性鼻炎及相关症状进行对症治疗和成人。
鼻喷雾剂市场按类型、应用、患者、分销渠道和地区分类。
抗组胺鼻喷雾剂市场占据了很大的收入份额,由于其广泛用于治疗过敏性鼻炎,预计到 2032 年将获得显着的增长。这些喷雾剂通过阻断组胺受体起作用,有效缓解过敏症状。随着患者寻求快速且持久的解决方案,製药公司继续开发和销售抗组胺鼻喷雾剂,从而促进了该细分市场的增长。例如,2022 年 6 月,拜耳的 Astepro 过敏鼻喷雾剂获得 FDA 批准可作为非处方药使用。它是第一个在美国被批准作为非处方药用于治疗过敏的无类固醇抗组胺鼻喷雾剂。
到2032年底,过敏性鼻炎应用领域的鼻喷雾剂市场份额有望积累可观的收入份额。随着全球过敏性鼻炎发病率的上升,对鼻喷雾剂作为主要治疗方式的需求也相应激增。由于鼻喷雾剂在治疗过敏性鼻炎方面的便利性和非侵入性,人们对鼻喷雾剂的偏好正在上升,这将对该细分市场的增长产生积极影响。
根据分销渠道,在因各种疾病寻求治疗的患者不断涌入的推动下,医院领域的鼻喷雾剂市场可能会在2023年至2032年期间以强劲的速度增长。此外,许多鼻喷雾剂都是处方型的,医院有足够的设备可以开具处方并将这些产品直接分发给患者。这种固有的能力确保了鼻喷雾剂的可靠和高效的供应链,使患者能够无缝地获得所需的药物,从而进一步增加到 2032 年该部门的收入。
由于人们越来越认识到鼻喷雾剂是治疗呼吸道疾病的一种方便有效的药物,亚太地区鼻喷雾剂行业将在 2032 年大幅扩张。此外,亚太地区人口的快速增长,与人口老龄化相一致,增加了通常需要鼻喷雾剂的慢性疾病的患病率。此外,许多亚太国家医疗保健基础设施的改善、医疗保健信息的获取以及可支配收入的增加,使得鼻喷雾剂更容易获得和负担得起,从而推动市场增长。
Nasal Spray Market is anticipated to experience robust growth during the forecast timeline from 2023 to 2032 due to the increasing prevalence of allergic rhinitis and sinusitis.
With rising environmental pollutants and changing lifestyles, more individuals are afflicted by these respiratory conditions, driving up demand for nasal sprays. According to the World Allergy Organization, more than 400 million individuals worldwide suffer from allergic rhinitis, which is often misdiagnosed and undertreated. It affects 10-30% of the adult general population and up to 40% of children in the United States, making it the sixth most prevalent chronic condition. Nasal sprays provide instant relief from congestion and related symptoms, offering a convenient solution for sufferers.
Moreover, pharmaceutical companies are actively developing innovative formulations to cater to this growing demand, further propelling the market growth. To cite an instance, in May 2023, Bausch Health Companies Inc. announced the launch of RYALTRIS®, a novel prescription therapy authorized by Health Canada for the symptomatic management of moderate mild to severe seasonal allergic rhinitis and associated symptoms in children, adolescents, and adults.
The nasal spray market is classified by type, application, patient, distribution channel, and region.
The antihistamine nasal spray market accounted for a substantial revenue share and is estimated to gain notable traction through 2032, attributed to their widespread use in the treatment of allergic rhinitis. These sprays work by blocking histamine receptors, alleviating allergy symptoms effectively. As patients seek rapid and long-lasting solutions, pharmaceutical companies continue developing and marketing antihistamine nasal sprays, contributing to the segment growth. For instance, In June 2022, Astepro allergy nasal spray from Bayer received FDA clearance for over-the-counter use. It is the very first steroid-free antihistamine nasal spray for the treatment of allergies to be approved for over-the-counter usage in the USA.
The nasal spray market share from the allergic rhinitis application segment is poised to amass considerable revenue share by the end of 2032. With the rising incidence of allergic rhinitis worldwide, there has been a corresponding surge in demand for nasal sprays as a primary mode of treatment. The preference for nasal sprays is rising due to their convenience and non-invasiveness in the management of allergic rhinitis, which will positively impact the segment growth.
Based on the distribution channel, the nasal spray market from the hospital segment could grow at a robust growth rate from 2023-2032, driven by the constant influx of patients seeking treatment for various medical conditions. Additionally, many nasal sprays are prescription-based, and hospitals are well-equipped to issue prescriptions and dispense these products directly to patients. This inherent capability ensures a reliable and efficient supply chain for nasal sprays, offering patients seamless access to the required medications, further bolstering the segment revenue through 2032.
The Asia Pacific nasal spray industry will expand significantly through 2032, driven by the increasing awareness of nasal sprays as a convenient and effective remedy for respiratory conditions. Additionally, the rapidly growing population in APAC, in line with the aging demographic, has increased the prevalence of chronic ailments that often require nasal sprays. Furthermore, the presence of improved healthcare infrastructure, access to healthcare information, and rising disposable income in many APAC countries have made nasal sprays more accessible and affordable, thereby driving market growth.